VERU

VERU INC. (The Female Health Company) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for the period ended June 30, 2009. The Company manufactures, markets, and sells the FC1 and FC2 female condoms, the only FDA-approved products under a woman's control that provide dual protection against unintended pregnancy and sexually transmitted infections (STIs), including HIV/AIDS. The Company operates manufacturing facilities in the United Kingdom (FC1) and Malaysia (FC2), with sales in 116 countries primarily through public sector agreements and commercial partners.

Key Financial Metrics

Note: The Company had no outstanding borrowings under its $1.5 million revolving credit facility as of June 30, 2009.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 23% ($1.3M) for the quarter and 10% ($1.8M) for the nine-month period compared to the prior year. This was driven by a 48% increase in unit volume, partially offset by a higher mix of lower-priced FC2 units.
• Profitability: Gross profit margins improved significantly to 48% (quarter) and 49% (nine months) from 39% and 41% in the prior year periods, respectively. This improvement is attributed to the higher gross margin profile of FC2 units and increased royalty income.
• Foreign Currency Impact: The quarter included a significant foreign currency transaction loss of $816,148 due to the strengthening of the British pound against the Malaysian ringgit and U.S. dollar, reversing a gain from the first quarter. For the nine-month period, the net impact was a gain of $183,672.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 6% for the quarter and 7% for the nine months, primarily due to higher compensation costs and stock-based incentive expenses. R&D expenses decreased as FC2 development concluded.

Outlook, Risks, and Contingencies

• UK Facility Evaluation: On August 5, 2009, the Company announced an evaluation of its UK manufacturing facility following decisions by two major customers to switch from FC1 (made in the UK) to FC2 (made in Malaysia). If no alternative is found, operations may cease, potentially resulting in one-time redundancy and lease charges. The evaluation is expected to conclude in approximately 90 days.
• Manufacturing Expansion: The Company is self-funding a 150% expansion of FC2 capacity in Malaysia, increasing annual capacity from 30 million to 75-80 million units. Completion is expected in the fourth quarter of fiscal 2009.
• Preferred Stock Redemption: The Company notified holders of Series 3 Preferred Stock of its intent to redeem all outstanding shares on August 13, 2009, as the common stock price exceeded the required threshold.
• Regulatory: FC2 received FDA approval in March 2009 and is expected to be available in the U.S. in August 2009. The Company relies heavily on public sector funding and government programs for HIV/AIDS prevention.

Investor Verification Checklist

• UK Facility Outcome: Monitor the conclusion of the 90-day evaluation of the UK facility to assess potential one-time charges and impact on FC1 supply chain.
• FC2 U.S. Launch: Verify the timeline and initial sales volume for FC2 in the U.S. market, expected to begin in August 2009.
• Currency Hedging: Review management's strategy for managing foreign currency risk, given the significant volatility in GBP/MYR/USD exchange rates impacting earnings.
• Preferred Stock Redemption: Confirm the execution of the Series 3 Preferred Stock redemption and its impact on cash flow and equity structure.
• Capital Expenditures: Track the completion of the Malaysia facility expansion and the associated $178,000 in outstanding purchase commitments.